Literature DB >> 19628649

Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.

Heribert Hänscheid1, Michael Lassmann, Markus Luster, Richard T Kloos, Christoph Reiners.   

Abstract

A simple method is presented to estimate the radiation-absorbed dose to the blood after radioiodine administration from a single external measurement of the whole-body retention in patients suffering from differentiated thyroid cancer. The blood dose is calculated applying the formalism of the Medical International Radiation Dose Committee under the assumptions that whole-body activity decays exponentially and that 14% of the whole-body residence time can be attributed to the blood. Accuracy and applicability of the method were tested based on data from 29 assessments, 18 pre-therapeutic tracer studies, and 11 ablation therapies, with whole-body and blood-retention measurements over at least 4 days. The mean of the absolute deviations between estimates and actual blood doses was found to be 14%, if external whole-body counting was performed on day 1 or 2 after radioiodine administration. This simple formalism is: 1) applicable to pre-therapeutic dosimetry for remnant ablation or treatment of metastases in a blood dose-based treatment concept and 2) applicable to blood-dose estimates after radioiodine therapy to determine radiation exposure. When combined with a measurement of the whole body retention 1 or 2 days after radioiodine administration this single time-point method closely approximates the classic, yet much more labor intensive multi-day dosimetry that measures both blood and whole-body activities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19628649     DOI: 10.1677/ERC-09-0076

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  14 in total

Review 1.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

Review 2.  Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.

Authors:  Massimo Salvatori; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04       Impact factor: 9.236

3.  Cytogenetic and dosimetric effects of (131)I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments.

Authors:  Márcia Augusta da Silva; Flávia Gomes Silva Valgôde; Júlia Armiliato Gonzalez; Hélio Yoriyaz; Maria Inês Calil Cury Guimarães; Maria Teresa Carvalho Pinto Ribela; Carlos Alberto Buchpiguel; Paolo Bartolini; Kayo Okazaki
Journal:  Radiat Environ Biophys       Date:  2016-03-24       Impact factor: 1.925

Review 4.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

5.  The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients.

Authors:  Frederik A Verburg; Michael Lassmann; Uwe Mäder; Markus Luster; Christoph Reiners; Heribert Hänscheid
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

6.  Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level.

Authors:  Heribert Hänscheid; Frederik Anton Verburg; Johannes Biko; Stefanie Diessl; Yuri E Demidchik; Valentina Drozd; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-02       Impact factor: 9.236

7.  Red bone marrow dose estimation using several internal dosimetry models for prospective dosimetry-oriented radioiodine therapy.

Authors:  Mohammad Abuqbeitah; Mustafa Demir; İffet Çavdar; Handan Tanyildizi; Nami Yeyin; Lebriz Uslu-Beşli; Levent Kabasakal; Nazenin İpek Işıkcı; Kerim Sönmezoğlu
Journal:  Radiat Environ Biophys       Date:  2018-10-08       Impact factor: 1.925

8.  Clinical experiences with radiation induced thyroid cancer after chernobyl.

Authors:  Christoph Reiners
Journal:  Genes (Basel)       Date:  2011-05-31       Impact factor: 4.096

9.  Calculation of Blood Dose in Patients Treated With 131I Using MIRD, Imaging, and Blood Sampling Methods.

Authors:  Elham Piruzan; Mahdi Haghighatafshar; Reza Faghihi; Seyed Mohammad Entezarmahdi
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

10.  Radioactive (131)Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting.

Authors:  Ramamoorthy Ravichandran; Naima Al Balushi
Journal:  World J Nucl Med       Date:  2016-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.